PGE₂ limits effector expansion of tumour-infiltrating stem-like CD8⁺ T cells.

ABSTRACT: Cancer-specific TCF1⁺ stem-like CD8⁺ T cells can drive protective anticancer immunity through expansion and effector cell differentiation^1-4; however, this response is dysfunctional in tumours. Current cancer immunotherapies^2,5-9 can promote anticancer responses through TCF1⁺ stem-like CD8⁺ T cells in some but not all patients. This variation points towards currently ill-defined mechanisms that limit TCF1⁺CD8⁺ T cell-mediated anticancer immunity. Here we demonstrate that tumour-derived prostaglandin E2 (PGE₂) restricts the proliferative expansion and effector differentiation of TCF1⁺CD8⁺ T cells within tumours, which promotes cancer immune escape. PGE₂ does no

SUBMITTER: Lacher SB 

PROVIDER: S-EPMC11078747 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature